Abstracts Archive - Page 53 of 2607 - ACR Meeting Abstracts

Abstract Number: 0499 • ACR Convergence 2025
Olokizumab Improves Patient-Reported Outcomes in Rheumatoid Arthritis MTX-IR and TNF-IR Patients up to 106 Weeks (Results from Clinical Phase III Program)
Roy Fleischmann¹, Eugen feist² and Josef Smolen³, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Helios Department of Rheumatology, Vogelsang-Gommern, Germany, ³Division of Rheumatology, Department of Medicine ³, Medical University of Vienna, Vienna, Austria, Vienna, Austria
Background/Purpose: Olokizumab (OKZ), an interleukin-6 inhibitor approved in several countries for managing rheumatoid arthritis (RA), was evaluated in previous phase III RCTs, demonstrating changes in…
Abstract Number: 0517 • ACR Convergence 2025
Gut Microbiota Dysbiosis and Clinical Predictors of Fatigue in Primary Sjögren’s Syndrome: A Multi-Omics Study
Qiguo Cui¹, Pan Wang², Bin Zhou¹ and QIn Huang³, ¹Southern Medical Univercity Nanfang Hospital, guang zhou, China (People's Republic), ²southern medical university Nanfang Hospital, Guangzhou, China (People's Republic), ³Nanfang Hospital, Guangzhou, China (People's Republic)
Background/Purpose: Fatigue affects 70% of primary Sjögren's syndrome (pSS) patients, but its mechanisms remain unclear. We investigated clinical predictors and gut microbiota associations in pSS-related…
Abstract Number: 0072 • ACR Convergence 2025
Impact of Baricitinib on Cardiovascular Health in Biologic-naïve Rheumatoid Arthritis patients: A Comparative Study with TNF Inhibitors and Conventional DMARDs
Chary López pedrera¹, Laura muñoz-Barrera², Rafaela Ortega-Castro³, Sagrario Corrales², Jerusalen Calvo Gutierrez⁴, Concepción Aranda Valera⁵, Lourdes Ladehesa⁶, Pilar Font⁷, Ismael Sanchez-Pareja², Elena Moreno-Caño⁵, M Carmen Abalos-Aguilera⁸, Christian Merlo-Ruiz⁸, MARIA ANGELES AGUIRRE ZAMORANO², Pedro Seguí-Azpilcueta⁹, Tomás Cerdó², Nuria Barbarroja¹⁰, Rocío González Conejero¹¹, Constantino Martínez¹¹, Carlos Pérez Sánchez¹² and Alejandro Escudero¹³, ¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ⁴Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Sevilla, Spain, ⁵IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Córdoba, Spain, ⁶IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, ⁷Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, SpainBiomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ⁸Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁹Radiology Service, Reina Sofia Hospital/Maimonides Institute for Research in Biomedicine of Cordoba/University of Cordoba, Spain, Córdoba, United Kingdom, ¹⁰Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹¹Servicio de Hematología, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB Pascual Parrilla., Murcia, Spain, ¹²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Andalucia, Spain
Background/Purpose: Therapeutic advances in RA have introduced effective treatments, including b/tsDMARDs such as Baricitinib. However, its cardiovascular safety profile remains unclear, partly due to the…
Abstract Number: 0064 • ACR Convergence 2025
Sclerostin from marrow adipogenic precursors is essential for bone and joint homeostasis in mice
Tailin He and Yifang Mei, Shenzhen Third People's Hospital, Shenzhen, China (People's Republic)
Background/Purpose: A novel mesenchymal subpopulation known as 'marrow adipogenic lineage precursors' (MALPs) has been identified, characterized by the expression of various adipocyte markers while lacking…
Abstract Number: 0121 • ACR Convergence 2025
The Prevalence and Clinical Significance of IgA Anticardiolipin and Anti-β2-Glycoprotein-I Antibody Isotypes in Antiphospholipid Antibody Positive Patients: Descriptive Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Registry
Emre Sahin¹, Yu (Ray) Zuo², Danieli Andrade³, Maria Tektonidou⁴, Vittorio Pengo⁵, Massimo Radin⁶, Chary López pedrera⁷, Diana Paredes-Ruiz⁸, H Michael Belmont⁹, Paul Fortin¹⁰, Denis WAHL¹¹, Ware Branch¹², Maria Gerosa¹³, Guilherme Ramires de Jesus¹⁴, Tatsuya Atsumi¹⁵, Maria Efthymiou¹⁶, Angela Tincani¹⁷, Esther Rodriguez-Almaraz¹⁸, Michelle Petri¹⁹, Ricard Cervera²⁰, Rohan Willis²¹, Katrien Devreese²², Maria Laura Bertolaccini²³, Hannah Cohen²⁴, Jason S. Knight² and Doruk Erkan¹, ¹Hospital for Special Surgery, New York, NY, ²University of Michigan, Ann Arbor, MI, ³University of Sao Paulo, São Paulo, São Paulo, Brazil, ⁴National and Kapodistrian University of Athens, Athens, Greece, ⁵Padova University Hospital, Padova, Italy, ⁶University of Turin, Turin, Turin, Italy, ⁷Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ⁸Biobizkaia Health Research Institute, Barakaldo, Spain, ⁹NYU School of Medicine, New York, NY, ¹⁰Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ¹¹University of Lorraine, Nancy, France, ¹²University of Utah Health Sciences Center, Salt Lake City, UT, ¹³University of Milan, Milano, Italy, ¹⁴Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Rio de Janeiro, Brazil, ¹⁵Hokkaido University, Sapporo, Japan, ¹⁶University College London, London, United Kingdom, ¹⁷ASST Spedali Civili-University of Brescia, Gussago, Brescia, Italy, ¹⁸Hospital Universitario ¹² de Octubre, Madrid, Spain, ¹⁹Johns Hopkins University School of Medicine, Timonium, MD, ²⁰Hospital Clinic Barcelona, Barcelona, Spain, ²¹University of Texas Medical Branch, Galveston, TX, ²²Ghent University, Gent, Belgium, ²³King's College London, London, United Kingdom, ²⁴University College London Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: The 2023 ACR/EULAR Antiphospholipid Syndrome (APS) Classification Criteria (CC) focus on IgG and IgM anticardiolipin (aCL) and anti-β2-glycoprotein-I antibodies (aβ2GPI). IgA isotypes were excluded…
Abstract Number: 0052 • ACR Convergence 2025
Profiling of MT-3534, a Humanized Monoclonal Antibody Targeting Peptidylarginine Deiminase 4, as a Candidate Drug for the Treatment of RA
Hisae Niki¹, Akitoshi Nishizawa², Yuuichi Ono¹, Makoto Yamazaki¹, Satoshi Takanashi³, Keiko Yoshimoto⁴, Mitsuhiro Akiyama³, Tsutomu Takeuchi⁵ and Yuko Kaneko⁴, ¹Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan, ²Mitsubishi Tanabe Pharma Corporation, Fujisawa, Kanagawa, Japan, ³Keio University School of Medicine, Tokyo, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ⁵Saitama Medical University and Keio University, Tokyo, Japan
Background/Purpose: Although the management of rheumatoid arthritis (RA) has been remarkably improved, there are still patients who have not responded to existing targeted drugs that…
Abstract Number: 0003 • ACR Convergence 2025
In Vivo Generation of anti-CD19 CAR T Cells Utilizing Circular RNA Encapsulated in Targeted Lipid Nanoparticles
Xiaoyu Pan¹, Xiaoning Wang¹, Zhihao Chen¹, Xiaowen Zou¹, Siqi Li¹, Jian Ye¹, Fei Lin¹, Yang He¹, Edo Kon², Peng Zhu¹, Mengyun Chen¹ and Weiyi Zhang¹, ¹RiboX Therapeutics, Shanghai, China (People's Republic), ²RiboX Therapeutics, Cambridge, MA
Background/Purpose: Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized cancer treatment and shown promise in addressing autoimmune diseases. However, current ex vivo CAR T-cell therapies…
Abstract Number: 0101 • ACR Convergence 2025
Enrichment of putative bacteria-reactive gut-derived IL-17+ tissue resident memory helper T cells in arthritic ankles in the SKG mouse model of spondyloarthritis
Benjamin Cai¹, Megan Soon², Zewen Kelvin Tuong², Mark Morrison², Anne-Sophie Bergot³ and Ranjeny Thomas⁴, ¹Frazer Institute, The University of Queensland, Brisbane, Queensland, Australia, ²Frazer Institute, The University of Queensland, Brisbane, Australia, ³Frazer Institute, The University of Queensland, Woolloongabba, Queensland, Australia, ⁴Frazer Institute, University of Queensland, Brisbane, Queensland, Australia
Background/Purpose: In spondyloarthropathy (SpA), arthritis is often associated with gut inflammation. The strong genetic association with HLA-B27 implicates involvement of T cells, but how gut…
Abstract Number: 0102 • ACR Convergence 2025
Iron Metabolism Dysregulation and Inflammation in Ankylosing Spondylitis: Role of SLC39A14 in Extracellular Matrix Remodeling
Dachun Zhuo¹, Yulong Tang², Xiaobei Ma², Chengchun Geng¹, Jiangnan Xie¹, Jiucun Wang² and Jing Liu¹, ¹Fudan University, Shanghai, Shanghai, China (People's Republic), ²Fudan university, Shanghai, China (People's Republic)
Background/Purpose: Iron metabolism dysregulation has been increasingly recognized as a key factor in the pathogenesis of inflammatory arthritis, with evidence linking altered iron homeostasis to…
Abstract Number: 0034 • ACR Convergence 2025
Meta-Analysis of GWAS data from 10,003 Sjögren’s Disease Cases Identifies Thirteen Sjögren’s Risk Loci.
Marcin Radziszewski¹, Bhuwan Khatri¹, Philip Stuart², Astrid Rasmussen¹, Kandice Tessneer¹, Cherilyn Pritchett-Frazee¹, Matthew Pattrick², Elena Pontarini³, michele Bombardieri⁴, Maureen Rischmueller⁵, Marika Kvarnström⁶, Torsten Witte⁷, Hendrika Bootsma⁸, Gwenny Verstappen⁹, Frans Kroese⁹, Arjan Vissink¹⁰, Sarah Pringle⁹, Athanasios Tzioufas¹¹, Clio Mavragani¹², Alan Baer¹³, Marta Alarcon-Riquelme¹⁴, Javier Martin¹⁵, Xavier Mariette¹⁶, Gaetane Nocturne¹⁷, Jacques-Olivier Pers¹⁸, Jacques-eric GOTTENBERG¹⁹, Wan-Fai Ng²⁰, Caroline Shiboski²¹, Kimberly Taylor²², Lindsey Criswell²³, Blake M. Warner²⁴, A. Darise Farris¹, Judith James¹, R Hal Scofield¹, Joel Guthridge¹, Daniel Wallace²⁵, Swamy Venuturupalli²⁶, Mike Brennan²⁷, Juliana Imgenberg-Kreuz²⁸, Lars Rönnblom²⁸, Eva Baecklund²⁹, Maija-Leena Eloranta²⁸, Svein Joar Augländ Johnsen³⁰, Roald Omdal³¹, Lara Aqrawi³², Øyvind Palm³³, Johan Brun³⁴, Daniel Hammenfors³⁴, Malin Jonsson³⁴ and Silke Appel³⁴, Sara Bucher³⁵, Helena Forsblad³⁶, Thomas Mandl³⁷, Per Eriksson³⁸, Marie Wahren-Herlenius⁶, Erik Abner³⁹, Tõnu Esko³⁹, Benjamin A. Fisher⁴⁰, Rachel Gordon⁴¹, Gabriela Hernandez-Molina⁴², Adrian Lee⁴³, Johann Gudjonsson⁴⁴, Lam Tsoi⁴⁴, Gunnel Nordmark²⁹ and Christopher Lessard¹,¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Michigan Medical School, Ann Arbor, MI, ³Queen Mary University of London, London, United Kingdom, ⁴Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, UK, London, United Kingdom, ⁵RheumatologySA, Adelaide, Australia, ⁶Karolinska Institutet, Stockholm, Sweden, ⁷Dept of Rheumatology and Immunology, Hannover, Niedersachsen, Germany, ⁸UMCG, Groningen, Netherlands, ⁹University Medical Center Groningen, Groningen, Netherlands, ¹⁰University of Groningen, Leek, Netherlands, ¹¹LAIKO HOSPITAL, Athens, Greece, ¹²National and Kapodistrian University of Athens, Athens, Greece, ¹³Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁴Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ¹⁵Department of Cell Biology and Immunology, Institute of Parasitology and Biomedicine López-Neyra, CSIC, Granada, Spain, ¹⁶Université Paris-Saclay, Le Kremlin Bicetre, France, ¹⁷University Paris Saclay, Le Kremlin Bicetre, Ile-de-France, France, ¹⁸CHU de Brest, Brest, France, ¹⁹Hautepierre Hospital, STRASBOURG, Alsace, France, ²⁰Newcastle University, Gateshead, United Kingdom, ²¹University of California San Francisco, San Francisco, CA, ²²UC San Francisco, San Francisco, CA, ²³NIH/NHGRI, Bethesda, MD, ²⁴National Institutes of Health, Bethesda, MD, ²⁵Cedars Sinai Medical Center, Studio City, CA, ²⁶Attune Health, Beverly Hills, CA, ²⁷Atrium Health, Charlotte, NC, ²⁸Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ²⁹Uppsala University, Uppsala, Sweden, ³⁰Stavanger University Hospital, Stavanger, Norway, ³¹Stavanger University Hospital, Stavanger, Nepal, ³²Kristiania University College, Oslo, Norway, ³³Oslo University Hospital, Oslo, Norway, ³⁴University of Bergen, Bergen, Norway, ³⁵Örebro University, Örebro, Sweden, ³⁶University of Gothenburg, Gothenburg, Sweden, ³⁷Lund University, Malmö, Sweden, ³⁸Linköping University, Linköping University, ³⁹University of Tartu, Tartu, Estonia, ⁴⁰ King’s College London, London, UK; Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK, ⁴¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁴²Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ⁴³University of Sydney, Sydney, Australia, ⁴⁴University of Michigan, Ann Arbor, MI.

Background/Purpose: Sjögren’s disease (SjD) is a systemic autoimmune condition with a complex genetic architecture. To date, 22 genome-wide significant (GWS) SjD risk loci have been…
Abstract Number: 0083 • ACR Convergence 2025
Confirmatory Factor Analysis of the Plutchik Suicide Risk Scale in Patients with Rheumatoid Arthritis
Pedro Quevedo¹, Javier mora², william garcia², alejandra Solano², juliana Muñoz² and Daniela Lopez², ¹San Rafael Cinic University Hospital, Bogota, Distrito Capital de Bogota, Colombia, ²san rafael clinic universtity hospital, Bogota, Distrito Capital de Bogota, Colombia
Background/Purpose: Prevalence of depression in RA patients ranging from 10% to 25%, making it the most common psychiatric disorder in this population. The Plutchik Suicide…
Abstract Number: 0115 • ACR Convergence 2025
Dysfunctional Mitophagy Propels Neutrophil Hyperactivity and Thrombosis in Antiphospholipid Syndrome
Ajay Tambralli¹, Emily Becker², Kaitlyn Sabb³, NaveenKumar Somanathapura¹, Srilakshmi Yalavarthi¹, Cyrus Sarosh⁴, Jacqueline Madison¹, Yu (Ray) Zuo¹ and Jason S. Knight¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, ³University of Michigan - Ann Arbor, Ann Arbor, MI, ⁴University of Michigan, Temperance, MI
Background/Purpose: Neutrophil hyperactivity and neutrophil extracellular trap (NET) release (NETosis) contribute to antiphospholipid syndrome (APS) pathogenesis. We recently discovered that APS patient neutrophils have more…
Abstract Number: 0078 • ACR Convergence 2025
Citrullinated Serum Albumin Is Not an Autoantigen in Rheumatoid Arthritis
Farheen Sultan Shaikh, cecilia mustelin, Xiaoxing Wang and Tomas Mustelin, University of Washington, Seattle, WA
Background/Purpose: Autoantibodies against citrullinated proteins (ACPAs) are diagnostic of rheumatoid arthritis (RA), an autoimmune disease primarily affecting synovial joints. Proteomic analyses have identified human serum…
Abstract Number: 0040 • ACR Convergence 2025
Identification Of A Novel, Expressed, Alternatively Spliced FCER1G Protein That Inhibits Receptor Function
Andrew Gibson¹, Jianming Wu², Chaoling Dong¹, R. Curtis Hendrickson¹, Travis Ptacek¹, Jeffrey Edberg¹ and Robert Kimberly¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Minnesota, Saint Paul, MN
Background/Purpose: The Tyrosine Activation Motif (ITAM)-containing FcRg chain, encoded by FCER1G, non-covalently couples with the immunoglobulin binding receptors, -- FcγRI (CD64), FcγRIIIa (CD16), and FcaRI…
Abstract Number: 0561 • ACR Convergence 2025
Patient Characteristics and Treatment Patterns of Traditional and Advanced Therapies Prior to First Secukinumab Intravenous (IV) Administration in Patients with Spondyloarthritis (SpA) in US Real-World Clinical Settings
Alan Kivitz¹, Linda Grinnell-Merrick², Tim Nguyen², Ariane Faucher³, Riley Taiji³, Francis Vekeman³ and Atul Singhal⁴, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³STATLOG, Inc, Montreal, QC, Canada, ⁴SouthWest Arthritis Research Group, Mesquite, TX
Background/Purpose: Since most approved biologics are administered subcutaneously, there is a need for alternate routes of delivery to treat patients with SpA. Secukinumab is an…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].